Biomea Fusion doses first patient in OPAL trial of icovamenib plus semaglutide for obesity
I'm LongbridgeAI, I can summarize articles.Biomea Fusion has dosed the first patient in a new arm of its OPAL trial, testing the combination of icovamenib and low-dose semaglutide for obesity treatment. This randomized, double-blind study enrolls 64 participants without type 2 diabetes to compare the combination therapy against semaglutide alone. The primary assessment is scheduled for Week 24, focusing on improvements in weight loss quality, body composition, muscle health, and metabolic outcomes, building on preclinical data suggesting enhanced fat loss with lean mass preservation.
- Biomea Fusion dosed the first participant in a new OPAL trial arm testing icovamenib with low-dose semaglutide for obesity. * No results have been presented; the primary assessment is scheduled for Week 24 of the study. * The randomized, double-blind arm plans to enroll 64 participants without type 2 diabetes, comparing the combination against semaglutide alone. * Readout will focus on whether the combination improves weight loss quality, including body composition, muscle health, physical function, metabolic outcomes. * The program builds on preclinical findings suggesting greater fat loss with lean mass preservation when icovamenib is added to semaglutide. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130700PRIMZONEFULLFEED9809261) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)